Cynvec has direct access to the first line cancer treatment clinicians and has established an extensive collaboration with medical oncologists and clinicians at New York University Medical School and Rutgers University.

In order to fully realize the power of oncolytic Sindbis viral vector platform, we are open to partnering with industrial leaders to expand our product development and deliver effective immunotherapies for cancer patients.